Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis

Liver International

Volumn 27, Issue 9, 2007, Pages 1226-1231

  Rigopoulou, Eirini I ^a   Davies, Edward T ^b   Bogdanos, Dimitrios Petrou ^b   Liaskos, Christos ^a,b,c   Mytilinaiou, Maria ^b   Koukoulis, George K ^a   Dalekos, George N ^a,c   Vergani, Diego ^b  

^a UNIVERSITY OF THESSALY   (Greece)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c INSTITUTE OF HUMAN PERFORMANCE AND REHABILITATION   (Greece)

Author keywords

Auto antibody; Auto immunity; Autoimmune disease; Cholestasis; Liver disease

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; MITOCHONDRION ANTIBODY; URSODEOXYCHOLIC ACID;

ADULT; AGED; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GREECE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PROGNOSIS; RAT; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; DISEASE PROGRESSION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOGLOBULIN ISOTYPES; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; MITOCHONDRIA, LIVER; PREDICTIVE VALUE OF TESTS;

EID: 35148835681     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01586.x     Document Type: Article

References (26)

1. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353: 1261-73.
2. Bogdanos DP, Baum H, Vergani D. Antimitochondrial and other autoantibodies. Clin Liver Dis 2003; 7: 759-77, vi.
3. Metcalf JV, Mitchison HC, Palmer JM, et al. Natural history of early primary biliary cirrhosis. Lancet 1996; 348: 1399-402.
4. Mitchison HC, Bassendine MF, Hendrick A, et al. Positive antimitochondrial antibody but normal alkaline phosphatase: Is this primary biliary cirrhosis? Hepatology 1986; 6: 1279-84.
5. Jefferis R. Structure-function relationships in human immunoglobulins. Neth J Med 1991; 39: 188-98.
6. Spiegelberg HL. Biological activities of immunoglobulins of different classes and subclasses. Adv Immunol 1974; 19:259-94.
7. Riggione O, Stokes RP, Thompson RA. Predominance of IgG3 subclass in primary cirrhosis. Br Med J (Clin Res Ed) 1983; 286: 1015-6.
8. Maran R, Dueymes M, Adler Y, et al. Isotypic distribution of anti-pyruvate dehydrogenase antibodies in patients with primary biliary cirrhosis and their family members. J Clin Immunol 1994; 14: 323-6.
9. French MA, Bernstein RM. Immunoglobulin G subclass distribution of autoantibodies in systemic sclerosis, primary biliary cirrhosis, and overlap syndromes. Ann Rheum Dis 1987; 46: 436-40.
10. Surh CD, Cooper AE, Coppel RL, et al. The predominance of IgG3 and IgM isotype antimitochondrial autoantibodies against recombinant fused mitochondrial polypeptide in patients with primary biliary cirrhosis. Hepatology 1988; 8: 290-5.
11. Moteki S, Leung PS, Dickson ER, et al. Epitope mapping and reactivity of autoantibodies to the E2 component of 2-oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2-oxoglutarate dehydrogenase complex. Hepatology 1996; 23: 436-44.
12. Rigopoulou EI, Davies ET, Pares A, et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 2005; 54: 528-32.
13. Dickson ER, Grambsch PM, Fleming TR, et al. Prognosis in primary biliary cirrhosis: Model for decision making. Hepatology 1989; 10: 1-7.
14. Chazouilleres O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy. Hepatology 1998; 28: 296-301.
15. Dalekos GN, Wedemeyer H, Obermayer-Straub P, et al. Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment. J Hepatol 1999; 30: 366-75.
16. Dalekos GN, Makri E, Loges S, et al. Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece. Eur J Gastroenterol Hepatol 2002; 14: 35-42.
17. Dalekos GN, Zachou K, Liaskos C, et al. Autoantibodies and defined target autoantigens in autoimmune hepatitis: An overview. Eur J Intern Med 2002; 13: 293-303.
18. Papadea C, Check IJ. Quality control of immunoglobulin G (IgG) subclass assays in the clinical laboratory. Clin Immunol Newslett 1988; 9: 104-6.
19. Klein F, Skvaril F, Vermeeren R, et al. The quantification of human IgG subclasses in reference preparations. Clin Chim Acta 1985; 150: 119-27.
20. Lindenborn-Fotinos J, Sayers TJ, Berg PA. Mitochondrial antibodies in primary biliary cirrhosis. VI. Association of the complement fixing antigen with a component of the mitochondrial F1-ATPase complex. Clin Exp Immunol 1982; 50: 267-74.
21. Van de Water J, Turchany J, Leung PS, et al. Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2. J Clin Invest 1993; 91: 2653-64.
22. Neuberger J, Thomson R. PBC and AMA - what is the connection? Hepatology 1999; 29: 271-6.
23. Wesierska-Gadek J, Penner E, Battezzati PM, et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 2006; 43: 1135-44.
24. Zuchner D, Sternsdorf T, Szostecki C, et al. Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology 1997; 26: 1123-30.
25. Nakamura M, Kondo H, Mori T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007; 45: 118-27.
26. Bogdanos DP, Liaskos C, Pares A, et al. Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. Hepatology 2007; 45: 1583.